Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disease (LPD) after hematopoietic stem cell or solid organ transplantation remains a life-threatening complication. Expression of the virus-encoded gene product, EBER, has been shown to prevent apoptosis via blockade of PKR activation. As PKR is a major cellular defense against Herpes simplex virus (HSV), and oncolytic HSV-1 (oHSV) mutants have shown promising antitumor efficacy in preclinical models, we sought to determine whether EBV-LPD cells are susceptible to infection by oHSVs. We tested three primary EBV-infected lymphocyte cell cultures from neuroblastoma (NB) patients as models of naturally acquired EBV-LPD. NB12 was the most susceptible, NB122R was intermediate and NB88R2 was essentially resistant. Despite EBER expression, PKR was activated by oHSV infection. Susceptibility to oHSV correlated with the expression of the HSV receptor, nectin-1. The resistance of NB88R2 was reversed by exogenous nectin-1 expression, whereas downregulation of nectin-1 on NB12 decreased viral entry. Xenografts derived from the EBV-LPDs exhibited only mild (NB12) or no (NB88R2) response to oHSV injection, compared with a NB cell line that showed a significant response. We conclude that EBV-LPDs are relatively resistant to oHSV virotherapy, in some cases, due to low virus receptor expression but also due to intact antiviral PKR signaling.
INTRODUCTION
Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disease (LPD) in immunocompromised patients, particularly after allogeneic bone marrow transplantation or solid organ transplantation, is a life-threatening complication of B-cell outgrowth normally controlled by T-cell surveillance. 1 Severity ranges from transient polyclonal B-cell lymphoproliferation to aggressive monoclonal lymphoma. Anti-CD20 antibody therapy and lympholytic chemotherapy can be therapeutic, yet these modalities are fraught with short-and long-term side effects, and in some cases are ineffective.
Attenuated, clinically-safe oncolytic herpes simplex virus (oHSV) mutants are emerging as promising therapeutics for cancer. 2 We postulated that EBV-infected cells may be particularly susceptible to lytic infection by a second herpes virus due to EBV-mediated inhibition of antiviral pathways. Although determinants of susceptibility to virus infection are still under investigation, blunted interferon and/or RNA-dependent protein kinase (PKR) responses have important roles in enabling lytic virus replication and spread. Additionally, virus receptor abundance is also being increasingly recognized as an important component of anticancer efficacy for oncolytic virotherapy.
The major antivirus cellular innate immunity defense mechanism is through PKR, which phosphorylates e-IF2a to halt protein synthesis, thereby limiting viral production. HSV-1 counteracts the PKR response by expressing ICP34.5 (encoded by the RL1, ICP34.5 or g 1 34.5 gene), which redirects cellular protein phosphatase-1 to dephosphorylate e-IF2a, thus restoring protein synthesis and allowing virus production. 3 Deletion of the gene encoding ICP34.5 markedly impairs virus replication in normal cells, but defects in the PKR response in many cancers enable replication of HSV vectors including ICP34.5 mutants. 4 EBERs, the EBV-encoded small RNAs, also block activation of PKR, 5 suggesting that EBV-infected cells may also be susceptible to infection with ICP34.5-deleted oHSVs.
A number of different cellular receptors mediate HSV-1 attachment and entry. The primary binding of virus to the cell surface occurs via the virus surface glycoproteins B and C binding to heparan sulfate proteoglycans that are relatively ubiquitous. A key interaction for entry then follows, with gD binding to one of the Herpes virus entry (Hve) mediators, primarily either HveA (also called HVEM) or HveC (also called nectin-1 or CD111). In some cases, HveB (also called nectin-2 or CD112) may be used for entry by HSV-1 laboratory strains with specific gD mutations or by HSV-2.
6,7 3-O sulfated heparan sulfate (3-OS HS) is also now appreciated to be a gD-binding HSV-1 receptor. 8 More importantly, receptor density directly correlates with virus entry efficiency. 9 Nectin-1 appears to be the most efficient receptor, and low or absent nectin-1 expression has been described to be limiting in some cases of thyroid carcinoma, head and neck squamous cell carcinoma and brain tumors [10] [11] [12] that may account for poor oncolytic virotherapeutic responses in those tumor cells.
We studied a serendipitous model of primary neuroblastoma (NB) patient-derived EBV-infected lymphocytes that are tumorigenic in immunodeficient mice. These cells displayed robust PKR activation following oHSV infection, yet some were still susceptible to lytic HSV-1 infection. Their relative susceptibility correlated with expression of the major HSV-1 entry receptor nectin-1. None of the cells were as susceptible as a NB line that was used for comparison, suggesting that oHSV may have limited use as a therapeutic strategy for EBV-LPD.
RESULTS
Tumor-initiating cell cultures from NB patients' bone marrow aspirates revealed EBV-LPD phenotype We initially began by studying tumor-initiating cells (TICs) from metastatic non-MYCN amplified NB patients' bone marrow aspirates, which display an immature neuronal phenotype and are tumorigenic in mice with very low cell numbers. 13, 14 A recent report suggested that these primary NB cultures were contaminated with patient-derived EBV-infected lymphoblastoid cells, 15 which at later passages, began to dominate the cultures. We obtained three tumor-initiating cells cultures including NB12 (passage 6), NB88R2 (passage 5) and NB122R (passage 4) 13, 14 and restricted their usage to passages between 6-12 for this study. In contrast to the typical NB immunophenotype GD2
verybright þ exhibited by the non-MYCN amplified NB cell line CHLA-20, the three TICs derived from bone marrow taken from patients with NB in our hands had lost the NB phenotype (GD2 low-neg /CD56 À ) and instead expressed CD20 þ /CD45 þ , suggesting a B-cell origin ( Figure 1a ) consistent with the previously reported CD19 and CD22 expression on these cells passaged in another laboratory. 15 These cells also expressed substantial amounts of nestin, the neural stem cell marker found in NB cells but also many types of progenitor cells including some hematopoietic cells. 16 We also detected EBER1 expression via PCR in all three tumor-initiating cells cultures (Figure 1b) as well as via in situ hybridization in xenograft tumors (Figure 1c ). For the purposes of this study, these cells then served as models of primary patient-derived EBV-LPD. Of note, we were unable to establish tumors in athymic nude animals, but were successful only in NOD.Cg-Prkdc scid Il2rg tm1Wjl/SzJ (NSG) mice, consistent with these cells representing LPD and requiring the absence of NK cells for tumorigenicity.
Differential susceptibility of EBV-LPDs to oHSV in vitro As expression of EBERs prevents IFN-a-mediated apoptosis through the inhibition of PKR signaling, 5 we postulated that EBV-positive cells would readily support productive oHSV replication and oncolysis, even using a g 1 34.5 mutant. We first examined the status of the PKR pathway in the three EBV-LPD cultures upon oHSV infection using oHSV rRp450, with an intact g 1 34.5 and thus predicted to not be reliant on PKR status of the infecting cell type. Although total PKR levels (both of the molecular weight close to 60 and 68 kDa, detected by antibodies D20 and B10, respectively) remained similar, phospho-PKR (T 451 ) with molecular weight close to 70 kDa and above was detected 24 h after infection with rRp450 including in the EBV-negative NB cell line CHLA-20 ( Figure 2a) . Notably, phospho-PKR (T 451 ) with molecular weight of 60 kDa was detected in the three EBV-LPDs that did not change upon virus infection. Phospho-eIF2a (Ser 52 ) was seen after virus infection across all cells but with a much weaker signal detected in NB88R2 and NB122R. Like PKR, total eIF2a remained the same upon rRp450 infection ( Figure 2a ). These results demonstrated that unlike what was found in a previous report, 5 the PKR pathway was not suppressed in these EBV-LPDs. We thus used ICP34.5-expressing viruses for all of our studies with these cells.
We next measured susceptibility to rRp450 (g 1 34.5-positive) virus-mediated cytotoxicity or lysis. The three EBV-LPDs showed differential responses, with NB12 the most sensitive, NB122R moderately sensitive and NB88R2 nearly resistant. In contrast, CHLA-20 was very susceptible to virus treatment (Figure 2b ). The cytotoxicity result correlated with virus replication in that NB12 reached the highest virus yield (B10 6 pfu/ml, a 4-log increase) among the three EBV-LPDs by 72 h post infection. In contrast, NB88R2 showed no significant virus production. The kinetics of virus replication was faster in CHLA-20, which reached 10 6 pfu/ml of virus yield by 48 h post infection, 24 h earlier than NB12 ( Figure 2c ).
As all of the cells activated PKR albeit to varying degrees, we hypothesized that the differences in virus replication may be due to differences in early stages of the virus life-cycle. We thus measured gene transfer using the EGFP-expressing virus, rQnestin34.5 17 (Figure 2d ). At 8 h after infection, more than 50% of NB12 and 80% of CHLA-20 were EGFP positive, suggesting the uptake of significant numbers of virus particles into these cells. In contrast, minimal virus entry was seen in NB88R2, suggesting that the transduction of these cells by oHSV may be due to the possibility of low or absent expression of HSV-1 entry receptors on these cells.
HSV entry receptor expression and usage in EBV-LPDs Based on variable gene transfer efficiency, we measured expression of HSV-1 entry receptors on these different EBV-LPD cells. By FACS analysis (Figure 3a ), nectin-1 was found to be in high abundance in NB12, intermediate in NB122R and CHLA-20, and barely detectable in NB88R2. HVEM was detectable at low levels in all three EBV-LPDs, but not in CHLA-20. NB88R2 and NB122R expressed very low levels of nectin-2. Relatively high levels of 3-OS HS were detected in NB122R and CHLA-20 ( Figure 3a ). RNA levels of these receptors (with heparan sulfate 3-O-sulfotransferase 3B1 (HS3ST3B1) used as surrogate marker for 3-OS HS) were also largely consistent with their surface protein expression, with the minor exception of CHLA-20 cells that had low but detectable nectin-2 RNA without detectable protein ( Figure 3b ). Among these receptors, the expression level of nectin-1 correlated with the results of virus-mediated cytotoxicity, virus replication and gene transfer in the EBV-LPDs. We confirmed the usage of canonical HSV-1 receptors by rQnestin-34.5 by measuring gene transfer in cells engineered to only express one HSV-1 receptor (Supplementary Figure S1a) . CHO cells normally lack expression of HSV-1 entry receptors, but have been engineered to express either nectin-1 (CHO-N1), 18 nectin-2 (CHO-N2), 6 or HVEM (CHO-A). 19 Both CHO-N1 and CHO-A cells but not CHO-N2 were susceptible to rQnestin34.5 infection as measured by quantitation of EGFP-positive cells (Supplementary Figure S1b) , suggesting that the virus mainly uses nectin-1 and HVEM but not nectin-2 for cell entry. This result is consistent with nectin-2 being selectively used only by a subset of HSV-1 gD mutant strains as well as HSV-2.
6,7 Therefore, the nectin-2 present on two of the EBV-LPD cells is not likely to be responsible for oHSV-1 virus entry.
To confirm receptor usage in the EBV-LPD cells, we infected cells with receptor-restricted gD mutant viruses that selectively utilize nectin-1 or HVEM for cell entry 20 ( Figure 3c ). Gene transfer in EBV-LPD cells again correlated with nectin-1 expression when infected with the wild-type gD virus (K26GFP) Exogenous expression of nectin-1 in EBV-LPDs overcomes the receptor barrier and further permits oHSV killing and replication In order to further prove that low expression of nectin-1 is the limiting factor for EBV-LPDs susceptibility to oHSV infection, we stably expressed nectin-1 in NB88R2 cells. The cytotoxicity of oHSV-1 mutants, rQnestin34.5 and its control version lacking expression of ICP34.5, rHSVQ1 (g034.5 À / À ), were tested on these clones and compared with the naïve NB88R2 and NB12. All cell groups infected with rHSVQ1 showed only minimal cytotoxicity at MOI ¼ 5, after 6 days (Figure 4a ), indicating that the attenuated mutant (ICP6 null ICP34.5 À / À ) is not potent enough to mediate effective killing in these cells, consistent with our previous finding of PKR activation. Without nectin-1 expression, NB88R2 cells retained 80-100% survival after 6 days of viral infection (Figure 4a , NB88R2 and Mieg3). In contrast, exogenous expression of nectin-1 in NB88R2 (Figure 4a , Nectin-1) increased rQnestin34.5-mediated cytotoxicity to levels comparable to the endogenous nectin-1-high NB12 line (P-values of Nectin-1 vs Mieg3 are o0.0001 for both MOI ¼ 1 and MOI ¼ 5, at day 4 and day 6). Consistently, without nectin-1 expression, there was no effective virus replication over 72 h in the cells (NB88R2 and Mieg3), whereas nectin-1 high EBV-LPDs (NB12 and Nectin-1) showed a 2-3 log increase in virus production after rQnestin34.5 infection (Figure 4b ). As expected, cells infected with rQnestin34.5 had significantly higher virus production than those infected with rHSVQ1 over time (Figure 4b , asterisks for black bar vs white bar). Moreover, trend analysis also revealed that in the nectin-1 high cells (NB12 and Nectin-1), viral production significantly increased over time when infected by rQnestin34.5 (both P-values for time dependence tests o0.0001) whereas it remained unchanged in nectin-1 null cells (NB88R2 and Mieg3), suggesting that both ICP34.5 (only present in rQnestin34.5) and nectin-1 are necessary for effective treatment in EBV-LPDs for oHSV-based therapy. (Surface nectin-1 expression was confirmed via flow cytometric analysis as shown in Figure 4c ) On the other hand, knockdown of nectin-1 expression in NB12 (Figure 4d , ShNectin-1) via lentiviralmediated shRNA transduction decreased rQnestin34.5 entry as compared with the naïve control (Figure 4d , Naive) or non-target shRNA control (Figure 4d, Sh02) . Together, these results provide both gain-and loss of function evidence that nectin-1 expression is necessary for EBV-LPD cells to be permissive for oHSV infection.
oHSV treatment showed antitumor efficacy in CHLA-20 and prolonged the survival of NB12, but had no effect on NB88R2 xenograft tumor models To determine the susceptibility of EBV-LPD tumors to oHSV therapy in vivo, xenograft models were established in NSG mice and rRp450 was used for direct intratumoral injection. In the CHLA-20 tumor model, all mice in the virus treatment group (8/8) showed tumor shrinkage (Supplementary Figure S2a) and seven had reached significant survival for at least 2 months after initial treatment (Figure 5a ). In EBV-LPD model animals, virus treatment slowed down tumor growth (Supplementary Figure S2b) and prolonged the survival of NB12 xenografts (Figure 5b) . Consistent with our cell line data, no significant differences in animal survival (Figure 5c ) or tumor growth (Supplementary Figure S2c) between the two groups were observed in the NB88R2 EBV-LPD line, indicating that these tumors were resistant to oHSV treatment. We also confirmed that xenograft tumors retained the fidelity of HSV entry receptor expression (Supplementary Figure S3) as appeared in the cell culture. Meanwhile, we observed some early deaths (tumor volume o2500 mm 3 ) in the virus-treated groups, one in the CHLA-20 group with a tumor o100 mm 3 at day 35, five in NB12 group with tumor volumes B2000 mm 3 between days 23-28 after the initial treatment (Figures 5a and 5b ), but none in the NB88R2 group. As most of the tissues were necrotic when we noticed the death of the animals, we were unable to perform any further analyses to identify the cause of death. We postulate the deaths were due to excessive virus replication in the responsive models (CHLA-20 and NB12) after such intensive treatment, though we cannot rule out the development of metastatic cancer in those animals. Unlike the high cure rate in CHLA-20, although NB12 tumors responded to oHSV treatment, all the recipients eventually succumbed to excessive tumor growth (Figure 5b ). In vivo virus replication revealed a significant difference in the kinetics of virus production between the two models. Although NB12 tumors showed only modest virus production with o2-log increase between 3-72 h post infection, CHLA-20 showed a marked virus yield of 4 logs (Figure 5d ). Together, our results demonstrate that with adequate HSV entry receptor expression (NB12), EBV-LPD can be modestly responsive to oHSV treatment.
DISCUSSION
Oncolytic virotherapy possesses considerable potential as a novel treatment modality for various forms of cancer and is being tested using different oncolytic viral vectors in a variety of tumor models. We studied HSV-1-based oncolytic therapy in several serendipitous tumor models of primary EBV-infected lymphocytes, reminiscent of EBV-derived LPD. We postulated that the predicted EBV-mediated inhibition of PKR signaling via EBER expression would render cells susceptible to oHSV virotherapy. Instead, we found PKR signaling intact, with cells only moderately supportive of oHSV replication. Moreover, we found that the effectiveness of oHSV virotherapy was dependent on HSV-1 entry receptor expression, tracking most closely with nectin-1 amongst the EBV-LPD cells analyzed. Gain-and loss-of-function studies as well as receptor-restricted recombinant mutant viruses confirmed the role of nectin-1 as the primary oHSV entry receptor in these cells. Our findings in this model system of EBV-LPD highlight the need to assess HSV-1 entry receptor expression when considering oHSV virotherapy, not only on a cancer-type basis but also on a patientby-patient basis.
EBV-LPD after hematopoietic stem cell or solid organ transplantation is a serious and often fatal complication. Although several therapeutic options have been somewhat effective for treating EBV-LPD, the overall results are unsatisfactory. 21 Expression of EBV-encoded small RNAs (EBER1 & EBER2) has been detected in all forms of EBV latently infected cells. 22 These polyA-negative, non-coding RNAs were shown to associate with several malignant phenotypes of Burkitt's lymphoma. 23 In Burkitt's lymphoma cells, expression of the EBERs was shown to inhibit IFNa induced apoptosis through direct binding and blocking of the activation of double-stranded RNA-activated protein kinase PKR, 5 indicating that this antiviral pathway is impaired in EBV-infected cells. Therefore, we postulated that EBV-LPD cells might be highly permissive for oHSV treatment. However, other studies suggested that the resistance to IFN-a-mediated apoptosis was not through PKR inhibition. 24, 25 Meanwhile, virus-associated RNA I expressed by adenovirus shows many similarities with the EBERs, such that EBERs were able to complement a virus-associated RNA I-deleted translational adenovirus defect 26, 27 and showed promising antitumor efficacy in EBV-associated diseases. 28 Altogether, these findings prompted us to study whether these EBV-LPD cultures respond to oHSV treatment and to identify the factor(s) involved in oHSV infection. In our study, the three EBV-LPD lines each expressed high levels of EBER1 (Figure 1b) , which was not present within the CHLA-20 NB control cells. Additionally, PKR species with molecular weights B70 kDa and above were activated upon oHSV in all three EBVLPDs as well as in the EBV-negative (and thus EBER-negative) NB cell line CHLA-20 ( Figure 2a) . Concomitantly, phosphorylation of eIF2a was also observed across all cells tested, suggesting our results favor the fact that EBERs do not directly inhibit IFN-amediated PKR pathway, at least in our primary EBV-LPD cells. Similarly, pT 451 PKR with molecular weight B60 kDa was observed in all three untreated EBV-LPDs and remained at similar levels following oHSV virus infection (Figure 2a) . PKR has been identified in nuclear and cytoplasmic fractions. Although the role of nuclear PKR remains unclear, pT 451 PKR, which represents the active PKR, was predominantly nuclear in high-risk myelodysplastic syndrome samples compared with mainly cytoplasmic form in low-risk samples. 29 Recently, studies in acute leukemia cells suggested that PKR in the nucleus was active and responded to stress. 30 Interestingly, the majority of nuclear pT 451 PKR in the study was B60kDa, 30 indicating that the constitutively activated PKR(60kDa) in our three EBV-LPDs that we had observed might be predominately located in the nucleus. Given the fact that these EBV-LPDs were much less susceptible to oHSV than the comparative NB cells, it will be interest to know whether activated PKR(60kDa) has a role in restricting oHSV replication. Based on our findings, we postulate that the stronger phosphoeIF2a signal in the two permissive lines NB12 and CHLA-20 was driven by more efficient entry of HSV, and thus more virusmediated PKR activation. The intensity of PKR response likely correlates with the amount of virus the cells receive. Therefore, we saw stronger phospho-PKR (70 kDa) signal in NB12 and CHLA-20 after virus infection, which ultimately led to more eIF2a phosphorylation. We think that the process between Figure 5 . Differential susceptibility of EBV-LPDs to oHSV in vivo. NB12, NB88R2 or CHLA-20 cells were implanted subcutaneously into the flanks of NSG mice. Implanted tumors were intratumorally injected with phosphate buffered saline (PBS) (solid line), 10 7 pfu rRp450 (dotted line) for a total of 5 treatments when tumor mass reached 150-250 mm 3 . Mice were sacrificed when the tumor size reached 2500 mm 3 or due to the appearance of morbidity. Kaplan-Meier survival curves were plotted and scored for statistical significance with the log-rank test for the results of (a) CHLA-20 xenografts, n ¼ 9 (PBS), n ¼ 8 (rRp450), (b) NB12 xenografts, n ¼ 13 (PBS), n ¼ 14 (rRp450) and (c) NB88R2 xenografts, n ¼ 15 (PBS), n ¼ 14 (rRp450). (d) Virus production in NB12 and CHLA-20 tumors. The implanted tumors were injected with 10 7 pfu of rRp450 using a single unfractionated dose. Tumors were harvested and homogenized at 3 and 72 h post infection for plaque assay. Solid triangles indicate mice sacrificed before tumor volume reached 2500 mm 3 .
Oncolytic HSV for EBV-lymphoproliferative disease P-Y Wang et al phosphorylation and dephosphorylation of eIF2a is dynamic, meaning while the increased entry of the virus stimulated more robust PKR responses, there is also more expression of ICP34.5 to redirect cellular protein phosphatase-1a to dephosphorylate some of the eIF2a, enabling productive virus replication. Owing to higher virus entry in the two permissive cells, we observed increased activated-PKR; therefore, overall more phospho-eIF2a appeared even though more dephosphorylation was also taking place. The susceptibility of our primary EBV-LPDs to oHSV correlated with major HSV-1 entry receptor nectin-1 expression which had an impact on virus entry, cytotoxicity and virus production. Notably, nectin-1 has been shown to be the major entry receptor in a few other types of tumors, including squamous cell carcinoma, 11 thyroid cancers 10 and gliomas. 12, 31 Although HVEM was expressed in all 3 EBV-LPDs (Figures 3a and b) , it did not appear to have a significant role in entry on these cells (Figure 3c ), suggesting that either there was a lack of co-receptor expression as indicated before 20 or that a loss of function mutation occurred as in a recent report. 32 As we observed only a modest effect of oHSV on tumor growth (Supplementary Figure S2) , even in the model expressing nectin-1 (Supplementary Figure S3) and only a modest increase in animal survival (Figure 5b ), our data are not particularly compelling for the application of oHSV for EBV-LPD. The underlying reason for relative resistance is unknown but is possibly due to the intact PKR response within the EBV-LPD lines. In contrast, the positive control NB line we used was highly susceptible to oHSV, confirming our previous report of the activity of oHSV in NB cell lines and xenografts. 33 Interestingly, CHLA-20 cells only expressed an intermediate level of nectin-1, with little to no detectable nectin-2 or HVEM (Figures 3a and b) . Moreover, the level of nectin-1 in the CHLA-20 cells was even less than that observed in the only slightly permissive NB12 EBV-LPD line (Figures 3a and b) . In contrast to the EBV-LPDs, CHLA-20 did express high levels of 3-OS HS, raising the possibility that this receptor may have a role in mediating virus entry in those cells. In fact, 3-OS HS has been shown to have an important role in HSV-1 entry in human mesenchymal stem cells 34 and human corneal fibroblasts. 35 Our data suggest that measuring the expression of HSV-1 entry receptors to identify those that lack all the major HSV entry receptors may be an important biomarker to identify cancer types or even individual cancer cases that may not be suitable for oHSV virotherapy.
MATERIALS AND METHODS

Cells and viruses
As previously described by Hansford et al. 13 and Pietras et al.
14 TICs were cultured in DMEM-F12 (3:1) with 2% B27 supplement (Life Technologies, Carlsbad, CA, USA) penicillin/streptomycin (100 U ml À 1 and 100 mg ml À 1 , respectively), bFGF (40 ng ml À 1 ) and EGF (20 ng ml À 1 ). Genotyping of short tandem repeats from these cells verified their identity with the original patients from which they were derived. CHLA-20 was cultured in IMDM containing 20% FBS, 0.5% MITO plus Serum Extender (BD Bioscience, San Jose, CA, USA) and penicillin/streptomycin (100 U ml À 1 and 100 mg ml À 1 , respectively). Vero cells (ATCC, Manassas, VA, USA), were cultured in Eagle's Minimal Essential Medium with 10% FBS and penicillin/ streptomycin (100 U ml À 1 and 100 mg ml À 1 , respectively). Chinese hamster ovary (CHO) cells negative for expression of HSV-1 entry receptors (CHO-K1) and CHO-K1 cells transduced to express human nectin-1 (CHO-N1) or nectin-2 (CHO-N2) were kind gifts from Patricia G. Spear (Northwestern University, IL, USA). CHO-K1 cells stably expressing human HVEM (CHO/A) were as described. 19 CHO cells were cultured in F12 medium containing 10% FBS, penicillin/streptomycin (100 U ml À 1 and 100 mg ml À 1 , respectively) and G418. Oncolytic HSV-1 mutants rRp450 (KOS strain), rHSVQ1 (F strain) and rQnestin34.5 (F strain) were described previously. 17, 36 Briefly, rRp450 contains the insertion of the rat CYP2B1 gene into UL39 (ICP6). rHSVQ1 contains a deletion in both copies of the g034.5 gene and an insertion of the green fluorescent protein (GFP) cDNA under control of the ICP6 promoter. rQnestin34.5 was derived from the parental virus rHSVQ1 by insertion of a single copy of the g034.5 gene under the control of the nestin enhancer and hsp68 minimal promoter into the UL39 region. The wild-type gD virus (K26GFP) and receptor-restricted derivatives K26-gD:d5-28V (nectin-1) and K26-gD:A3C/Y38C (HVEM) were engineered as previously described. 20 All virus stocks were produced and purified by the Virus Production Core at the University of Pittsburgh School of Medicine.
Flow cytometry
Tumor and CHO cultured cells were dispersed into single cell suspensions via mechanical trituration or a nonenzymatic cell dissociation buffer (Sigma-Aldrich, St Louis, MO, USA) treatment if needed. Xenograft tumors were harvested from animals, transferred to phosphate buffered saline, cut into small pieces with a scalpel and then digested for 1 h at 37 1C in Liberase Blenzyme3 (25 mg ml À 1 , Roche Applied Science, Indianapolis, IN, USA). The cellular suspensions were then passed through a 70 mm cell strainer and centrifuged. The cell pellet was then treated with red blood cell lysing buffer (Sigma-Adrich), washed and suspended in phosphate buffered saline. Analyses were performed on the BD FACSCanto II flow cytometer (BD, Franklin Lakes, NJ, USA) using FlowJo 9.4.10 analyzing software (Tree Star Inc., Ashland, OR, USA). Single-cell suspensions of B1 Â 10 6 elements were treated with 10% FcR blocking reagent (Miltenyi Biotec Inc., Auburn, CA, USA) for 10 min at 4 1C and then stained with directly conjugated antibodies (Abs) directed against the following human cell surface markers: CD20 fluorescein isothiocyanate conjugated, CD45 phycoerythrin conjugated, CD56 allophycocyanin (APC) conjugated, CD81 phycoerythrin conjugated (above Abs were all from BD Bioscience, San Jose, CA, USA). The following unconjugated Abs were also used: human ganglioside GD2 (BD Biosciences), antihuman nectin-1, nectin-2 and HVEM (above Abs were all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). After applying the unconjugated Abs or their isotype controls, cells were stained with a secondary fluorescein isothiocyanate-conjugated goat antimouse IgG (BD Biosciences). Dead cells were detected by adding 7-amino-actinomycin D (7-AAD, BD Bioscience) to each tube 10 min prior to analysis. In Figure 4c , phycoerythrin conjugated goat antimouse IgG (Southern Biotech, Birmingham, AL, USA) was used as the secondary antibody. 
EBV in situ hybridization
Excised xenograft tumors were fixed in 10% formalin and then processed and stained by the Cincinnati Children's Hospital Histology Core. Tissue sections were probed with Digoxigenin-UTP-labeled EBER1 oligo and then visualized with anti-Digoxin À Biotin (Sigma-Aldrich) and the Blue Map Detection Kit (Ventana Medical Systems, Tucson, AZ, USA). Nuclear Fast Red (Polysciences, Inc., Warrington, PA, USA) was used as a counterstain. Staining was performed on an automated platform Ventana Discovery (Ventana Medical Systems).
Cell survival/MTS assay Cells were plated in 96-well dishes at 3 Â 10 3 cells/well, incubated at 37 1C for 1-2 h and then infected with oncolytic HSV mutants at MOI 0.001, 0.01, 0.1 and 1.0 or higher in quadruplicate. The assays were performed using Cell Titer96 AQuesous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI, USA) per manufacturer's instructions on days 2, 4 and 6. Results were presented as percent cell survival compared with uninfected controls.
Virus production
Tumor cells were plated in 24-well dishes at 5 Â 10 4 cells per well, incubated at 37 1C for 2 h, and infected with viruses at MOI 0.01. Plates were gently shaken every 20 min for 2 h. At 2, 24, 48 and 72 h post infection, both cells and supernatants were harvested, freeze-thawed three times, diluted and titered by standard plaque assay on Vero cells. 38 
